NHG-Richtlijnen
NHG-Standaard
M90
2.0
november 2017
november 2017
L. Bewegingsapparaat

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Beleid artritis algemeen

Naar Volledige tekst ›

Beleid jichtartritis

Naar Volledige tekst ›

Aanvalsbehandeling

Naar Volledige tekst ›

Urinezuurverlagende therapie

Naar Volledige tekst ›

Reactieve of ongedifferentieerde artritis

Naar Volledige tekst ›

Reumatoïde artritis

Naar Volledige tekst ›

Verwijzing en/of consultatie bij artritiden

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Kernboodschappen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Scope

Naar Samenvatting ›

Achtergronden

Naar Samenvatting ›

Begrippen

Naar Samenvatting ›

Epidemiologie

Naar Samenvatting ›

Pathofysiologie, etiologie, beloop en prognose

Naar Samenvatting ›

Bacteriële artritis

Naar Samenvatting ›

Jichtartritis

Naar Samenvatting ›

Reactieve artritis

Naar Samenvatting ›

Reumatoïde artritis

Naar Samenvatting ›

Overige perifere artritiden

Naar Samenvatting ›
Spondyloartritis (SpA)
Naar Samenvatting ›
Ongedifferentieerde artritis
Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

Anamnese

Naar Samenvatting ›

Werkdiagnose

Naar Samenvatting ›

Anamnese inflammatoire rugklachten

Naar Samenvatting ›

Overige aandachtspunten bij de anamnese

Naar Samenvatting ›

Lichamelijk onderzoek

Naar Samenvatting ›

Algemeen

Naar Samenvatting ›

Inspectie

Naar Samenvatting ›

Palpatie

Naar Samenvatting ›

Bewegingsonderzoek

Naar Samenvatting ›

Pijn en beperking

Naar Samenvatting ›

Differentiële diagnose

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

Algemeen aanvullend onderzoek

Naar Samenvatting ›

Bacteriële artritis

Naar Samenvatting ›

Jichtartritis

Naar Samenvatting ›
Gewrichtspunctie
Naar Samenvatting ›

Reactieve artritis

Naar Samenvatting ›

Reumatoïde artritis

Naar Samenvatting ›

Evaluatie

Naar Samenvatting ›

Bacteriële artritis

Naar Samenvatting ›

Jichtartritis

Naar Samenvatting ›

Reactieve artritis

Naar Samenvatting ›

Reumatoïde artritis

Naar Samenvatting ›

Differentiële diagnostiek

Naar Samenvatting ›

Ongedifferentieerde artritis

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Spoed

Naar Samenvatting ›

Beleid artritis algemeen

Naar Samenvatting ›

Voorlichting en niet-medicamenteuze adviezen

Naar Samenvatting ›

Thuisarts

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

Beleid jichtartritis

Naar Samenvatting ›

Voorlichting, adviezen en niet-medicamenteuze behandeling

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›
Urinezuurverhogende medicatie
Naar Samenvatting ›
Prednisolon of NSAID’s
Naar Samenvatting ›
Prednisolon
Naar Samenvatting ›
NSAID’s
Naar Samenvatting ›
Colchicine
Naar Samenvatting ›
Intra-articulaire corticosteroïden
Naar Samenvatting ›
Urinezuurverlagende therapie
Naar Samenvatting ›
Allopurinol
Naar Samenvatting ›
Benzbromaron en febuxostat
Naar Samenvatting ›

Reactieve of ongedifferentieerde artritis

Naar Samenvatting ›

Reactieve artritis mogelijk veroorzaakt door lymeziekte

Naar Samenvatting ›

Reumatoïde artritis

Naar Samenvatting ›

Aandachtspunten voor huisarts bij gebruik DMARD’s

Naar Samenvatting ›
Bijwerkingen
Naar Samenvatting ›
Comedicatie
Naar Samenvatting ›
Zwangerschap en preconceptionele fase
Naar Samenvatting ›
Infectie
Naar Samenvatting ›
Griepvaccinatie
Naar Samenvatting ›
Vaccinaties
Naar Samenvatting ›
Beleid in de stabiele fase
Naar Samenvatting ›

Consultatie en verwijzing

Naar Samenvatting ›

Referenties

  1. Nielen MMJ. Incidentie- en prevalentie van gezondheidsproblemen in de Nederlandse huisartsenpraktijk (2016). Ga naar bron
  2. Drenth JP, Van der Meer JW. The inflammasome--a linebacker of innate defense. N Engl J Med 2006;355:730-2.
  3. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010;233:218-32.
  4. Mylona EE, Mouktaroudi M, Crisan TO, Makri S, Pistiki A, Georgitsi M, et al. Enhanced interleukin-1beta production of pbmcs from patients with gout after stimulation with toll-like receptor-2 ligands and urate crystals. Arthritis Res Ther 2012;14:R158.
  5. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
  6. Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 2001;28:577-80.
  7. Levinson DJ, Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993.
  8. Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M, et al. Epidemiology of gout and hyperuricaemia in italy during the years 2005-2009: a nationwide population-based study. Ann Rheum Dis 2013;72:694-700.
  9. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the us general population: NHANES 2007-2008. Am J Med 2012;125:679-87.e1.
  10. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5.
  11. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the normative aging study. Am J Med 1987;82:421-6.
  12. Andersson HI, Leden I. Increased serum uric acid--a marker of non-gouty widespread pain? A study of female patients with inflammatory and non-inflammatory pain. Scand J Rheumatol 2006;35:261-7.
  13. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004;363:1277-81.
  14. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. Bmj 2008;336:309-12.
  15. Zgaga L, Theodoratou E, Kyle J, Farrington SM, Agakov F, Tenesa A, et al. The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS One 2012;7:e38123.
  16. Choi HK, Liu S, Curhan G. Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the third national health and nutrition examination survey. Arthritis Rheum 2005;52:283-9.
  17. McAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the atherosclerosis risk in communities cohort study. Arthritis Rheum 2012;64:121-9.
  18. Pascual E, Perdiguero M. Gout, diuretics and the kidney. Ann Rheum Dis 2006;65:981-2.
  19. Savage PJ, Pressel SL, Curb JD, Schron EB, Applegate WB, Black HR, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the systolic hypertension in the elderly program. SHEP cooperative research group. Arch Intern Med 1998;158:741-51.
  20. Krishnan E, Kwoh CK, Schumacher HR, Kuller L. Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 2007;49:298-303.
  21. Whelton A. Hyperuricemia and hypertension: a confluence of concepts. Hypertension 2012;60:1112-3.
  22. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, et al. Uric acid and survival in chronic heart failure: Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003;107:1991-7.
  23. Harzand A, Tamariz L, Hare JM. Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition. Congest Heart Fail 2012;18:179-82.
  24. Bellomo G, Venanzi S, Saronio P, Verdura C, Narducci PL. Prognostic significance of serum uric acid in women with gestational hypertension. Hypertension 2011;58:704-8.
  25. Puig JG, Martinez MA, Mora M, Fraile JM, Montoya F, Torres RJ. Serum urate, metabolic syndrome, and cardiovascular risk factors. A population-based study. Nucleosides Nucleotides Nucleic Acids 2008;27:620-3.
  26. Janssens PMW, De Abreu RA, Hamel BCJ. Een patient met verhoogd urinezuur en een geslachtsgebonden overervende ziekte. Ned Tijdschr Klin Chem Labgeneesk 2003b;28:370-5.
  27. Dalbeth N, Wong S, Gamble GD, Horne A, Mason B, Pool B, et al. Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis 2010;69:1677-82.
  28. Choi HK, Curhan G. Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 2007;57:816-21.
  29. Haj Mouhamed D, Ezzaher A, Neffati F, Douki W, Gaha L, Najjar MF. Effect of cigarette smoking on plasma uric acid concentrations. Environ Health Prev Med 2011;16:307-12.
  30. Juraschek SP, Miller ER, 3rd, Gelber AC. Effect of oral vitamin c supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken) 2011;63:1295-306.
  31. Flynn TJ, Phipps-Green A, Hollis-Moffatt JE, Merriman ME, Topless R, Montgomery G, et al. Association analysis of the slc22a11 (organic anion transporter 4) and slc22a12 (urate transporter 1) urate transporter locus with gout in new zealand case-control sample sets reveals multiple ancestral-specific effects. Arthritis Res Ther 2013;15:R220.
  32. Torres RJ, De Miguel E, Bailen R, Banegas JR, Puig JG. Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. J Rheumatol 2014;41:1863-70.
  33. Janssens HJ, Fransen J, Van de Lisdonk EH, Van Riel PL, Van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010a;170:1120-6.
  34. Chen SY, Chen CL, Shen ML, Kamatani N. Clinical features of familial gout and effects of probable genetic association between gout and its related disorders. Metabolism 2001;50:1203-7.
  35. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the framingham study. J Clin Epidemiol 1988;41:237-42.
  36. Janssens HJ, Van de Lisdonk EH, Bor H, Van den Hoogen HJ, Janssen M. Gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003a;20:413-6.
  37. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006;54:2688-96.
  38. Rainer TH, Cheng CH, Janssens HJ, Man CY, Tam LS, Choi YF, et al. Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial. Ann Intern Med 2016;164:464-71.
  39. Clarson LE, Hider SL, Belcher J, Heneghan C, Roddy E, Mallen CD. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the uk clinical practice research datalink. Ann Rheum Dis 2015;74:642-7.
  40. Krishnan E. Gout and the risk for incident heart failure and systolic dysfunction. BMJ Open 2012;2:e000282.
  41. Kuo CF, Yu KH, See LC, Chou IJ, Ko YS, Chang HC, et al. Risk of myocardial infarction among patients with gout: a nationwide population-based study. Rheumatology (Oxford) 2013;52:111-7.
  42. Perez-Ruiz F, Martinez-Indart L, Carmona L, Herrero-Beites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis 2014;73:177-82.
  43. Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007;34:1566-8.
  44. Tarng DC, Lin HY, Shyong ML, Wang JS, Yang WC, Huang TP. Renal function in gout patients. Am J Nephrol 1995;15:31-7.
  45. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014;66:185-96.
  46. Choi HK, Soriano LC, Zhang Y, Rodriguez LA. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. Bmj 2012;344:d8190.
  47. Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012;71:1448-53.
  48. Hueskes BA, Roovers EA, Mantel-Teeuwisse AK, Janssens HJ, Van de Lisdonk EH, Janssen M. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012;41:879-89.
  49. Singh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011;23:192-202.
  50. Janssens HJ, Janssen M, Van de Lisdonk EH, Fransen J, Van Riel PL, Van Weel C. Limited validity of the american college of rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2010b;69:1255-6.
  51. Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: an american college of rheumatology/european league against rheumatism collaborative initiative. Ann Rheum Dis 2015;74:1789-98.
  52. Kienhorst LBE, Janssen M, Fransen J, Van de Lisdonk EH, Janssens HJEM. Artritis van de grote teen is niet altijd jicht. Huisarts Wet 2015d;58:294-8.
  53. Lissner L, Heitmann BL, Lindroos AK. Measuring intake in free-living human subjects: a question of bias. Proc Nutr Soc 1998;57:333-9.
  54. Moi JH, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for chronic gout. Cochrane Database Syst Rev 2013a;5:CD010039.
  55. Moi JH, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for acute gout. Cochrane Database Syst Rev 2013b;11:CD010519.
  56. Qaseem A, Harris RP, Forciea MA. Management of acute and recurrent gout: a clinical practice guideline from the american college of physicians. Ann Intern Med 2017;166:58-68.
  57. Aho K, Heliovaara M. Risk factors for rheumatoid arthritis. Ann Med 2004;36:242-51.
  58. De Vries N. Genetic aspects of rheumatoid arthritis. Nijmegen: Katholieke Universiteit Nijmegen, 2001.
  59. Bijlsma JWJ, Van Laar JM. Leerboek reumatologie en klinische immunologie. Houten: Bohn Stafleu van Loghum, 2013.
  60. Van der Helm-Van Mil AH, Toes RE, Huizinga TW. Genetic variants in the prediction of rheumatoid arthritis. Ann Rheum Dis 2010;69:1694-6.
  61. Yarwood A, Huizinga TW, Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology (Oxford) 2016;55:199-209.
  62. Van der Horst-Bruinsma IE, Franssen MJAM, Oostveen JCM, Van Denderen JC, Leijsma MK, De Sonnaville PBJ, et al. Richtlijn voor de diagnostiek en behandeling van axiale spondyloartritis (2014). Ga naar bron
  63. Van der Korst JK. Artritis op de schaal van ritchie oftewel: reumatologie als klinimetrie avant la lettre. Ned Tijdschr Geneeskd 1990;134:422-3.
  64. Bull BS, Westengard JC, Farr M, Bacon PA, Meyer PJ, Stuart J. Efficacy of tests used to monitor rheumatoid arthritis. Lancet 1989;2:965-7.
  65. Peters RH, Rasker JJ, Jacobs JW, Prevo RL, Karthaus RP. Bacterial arthritis in a district hospital. Clin Rheumatol 1992;11:351-5.
  66. Weston VC, Jones AC, Bradbury N, Fawthrop F, Doherty M. Clinical features and outcome of septic arthritis in a single uk health district 1982-1991. Ann Rheum Dis 1999;58:214-9.
  67. Kienhorst LB, Janssens HJ, Fransen J, Janssen M. The validation of a diagnostic rule for gout without joint fluid analysis: a prospective study. Rheumatology (Oxford) 2015a;54:609-14.
  68. Rigby AS, Wood PH. Serum uric acid levels and gout: what does this herald for the population? Clin Exp Rheumatol 1994;12:395-400.
  69. Sivera F, Andres M, Falzon L, Van der Heijde DM, Carmona L. Diagnostic value of clinical, laboratory, and imaging findings in patients with a clinical suspicion of gout: a systematic literature review. J Rheumatol Suppl 2014;92:3-8.
  70. German DC, Holmes EW. Hyperuricemia and gout. Med Clin North Am 1986;70:419-36.
  71. Nesher G, Moore TL. Clinical presentation and treatment of arthritis in the aged. Clin Geriatr Med 1994;10:659-75.
  72. Graf SW, Buchbinder R, Zochling J, Whittle SL. The accuracy of methods for urate crystal detection in synovial fluid and the effect of sample handling: a systematic review. Clin Rheumatol 2013;32:225-32.
  73. Kienhorst LB, Janssens HJ, Eijgelaar RS, Radstake TR, Van Riel PL, Janssen M. The detection of monosodium urate crystals in synovial fluid after long-term and varying storage conditions. Joint Bone Spine 2015b;82:470-1.
  74. Tausche AK, Gehrisch S, Panzner I, Winzer M, Range U, Bornstein SR, et al. A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals. J Clin Rheumatol 2013;19:241-5.
  75. Dieppe P, Swan A. Identification of crystals in synovial fluid. Ann Rheum Dis 1999;58:261-3.
  76. Jacobs JW, Bijlsma JW. Jicht: de huidige visie op ontstaan, diagnostiek en therapie. Ned Tijdschr Geneeskd 1996;140:187-91.
  77. Von Essen R, Holtta AM, Pikkarainen R. Quality control of synovial fluid crystal identification. Ann Rheum Dis 1998;57:107-9.
  78. Lumbreras B, Pascual E, Frasquet J, Gonzalez-Salinas J, Rodriguez E, Hernandez-Aguado I. Analysis for crystals in synovial fluid: training of the analysts results in high consistency. Ann Rheum Dis 2005;64:612-5.
  79. CBO. Richtlijn lymeziekte (2013). Ga naar bron
  80. Van der Heijde DM, Van Riel PL, Van Rijswijk MH, Van de Putte LB. Influence of prognostic features on the final outcome in rheumatoid arthritis: a review of the literature. Semin Arthritis Rheum 1988;17:284-92.
  81. Hooijkaas H, Mohrmann K, Smeets LC, Souverijn JHM, Tax GHM. Handboek medische laboratoriumdiagnostiek. Houten: Prelum Uitgevers, 2013.
  82. Bampton JL, Cawston TE, Kyle MV, Hazleman BL. Measurement of rheumatoid factors by an enzyme-linked immunosorbent assay (elisa) and comparison with other methods. Ann Rheum Dis 1985;44:13-9.
  83. Pop P. Waarde van aanvullend onderzoek in de huisartspraktijk. Tijdschr Huisartsgeneesk 1996;13:411-20.
  84. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34.
  85. Gao IK, Haas-Wohrle A, Mueller KG, Lorenz HM, Fiehn C. Determination of anti-ccp antibodies in patients with suspected rheumatoid arthritis: does it help to predict the diagnosis before referral to a rheumatologist? Ann Rheum Dis 2005;64:1516-7.
  86. Girelli F, Foschi FG, Bedeschi E, Calderoni V, Stefanini GF, Martinelli MG. Is anti cyclic citrullinated peptide a useful laboratory test for the diagnosis of rheumatoid arthritis? Allerg Immunol (Paris) 2004;36:127-30.
  87. Vallbracht I, Rieber J, Oppermann M, Forger F, Siebert U, Helmke K. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004;63:1079-84.
  88. Van Gaalen FA, Linn-Rasker SP, Van Venrooij WJ, De Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.
  89. Vossenaar ER, Van Venrooij WJ. Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis. Arthritis Res Ther 2004;6:107-11.
  90. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.
  91. Brook A, Corbett M. Radiographic changes in early rheumatoid disease. Ann Rheum Dis 1977;36:71-3.
  92. Scott DL, Coulton BL, Popert AJ. Long term progression of joint damage in rheumatoid arthritis. Ann Rheum Dis 1986;45:373-8.
  93. Van der Heijde DM, Boers M. De waarde van rontgenfoto’s bij reumatoide artritis. Ned Tijdschr Geneeskd 1997;141:1725-30.
  94. Taylor WJ, Fransen J, Dalbeth N, Neogi T, Schumacher HR, Brown M, et al. Performance of classification criteria for gout in early and established disease. Ann Rheum Dis 2016;75:178-82.
  95. Lee KH, Choi ST, Lee SK, Lee JH, Yoon BY. Application of a novel diagnostic rule in the differential diagnosis between acute gouty arthritis and septic arthritis. J Korean Med Sci 2015;30:700-4.
  96. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977;20:895-900.
  97. Malik A, Schumacher HR, Dinnella JE, Clayburne GM. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009;15:22-4.
  98. Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken) 2015;67:891-7.
  99. Emery P, Breedveld FC, Dougados M, Kalden JR, Schiff MH, Smolen JS. Early referral recommendation for newly diagnosed rheumatoid arthritis: Evidence based development of a clinical guide. Ann Rheum Dis 2002;61:290-7.
  100. Lorenz EC, Michet CJ, Milliner DS, Lieske JC. Update on oxalate crystal disease. Curr Rheumatol Rep 2013;15:340.
  101. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al. European league against rheumatism recommendations for calcium pyro-phosphate deposition. Part i: terminology and diagnosis. Ann Rheum Dis 2011b;70:563-70.
  102. Kienhorst LBE, Janssen M. Jicht en pseudojicht (2015). Bijblijven. Ga naar bron
  103. Jacobs JW, Bijlsma JW. Calciumpyrofosfaat-artropathie: Meer dan chondrocalcinose en pseudojicht. Ned Tijdschr Geneeskd 1992;136:119-22.
  104. Richette P, Bardin T, Doherty M. An update on the epidemiology of calcium pyrophosphate dihydrate crystal deposition disease. Rheumatology (Oxford) 2009;48:711-5.
  105. Beutler A, Schumacher HR, Jr. Gout and ‘pseudogout’. When are arthritic symptoms caused by crystal deposition? Postgrad Med 1994;95:103-6.
  106. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al. Eular recommendations for calcium pyrophosphate deposition. Part ii: management. Ann Rheum Dis 2011a;70:571-5.
  107. NVVG. Richtlijn reumatoïde artritis en participatie in arbeid (2015). Ga naar bron
  108. CBO. Zorgmodule arbeid 1.0. Begeleiding rondom arbeidsparticipatie van chronisch zieken (2014). Ga naar bron
  109. Staessen J. The determinants and prognostic significance of serum uric acid in elderly patients of the european working party on high blood pressure in the elderly trial. Am J Med 1991;90:50s-4s.
  110. Janssens HJ, Van de Lisdonk EH, Janssen M, Van den Hoogen HJ, Verbeek AL. Jicht niet uitgelokt door diuretica in een patient-controleonderzoek in de huisartspraktijk. Ned Tijdschr Geneeskd 2007;151:472-7.
  111. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2008b:CD005521.
  112. Man CY, Cheung IT, Cameron PA, Rainer TH. Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial. Ann Emerg Med 2007;49:670-7.
  113. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout--a systematic review. Rheumatology (Oxford) 2006;45:1422-31.
  114. Van Durme CM, Wechalekar MD, Buchbinder R, Schlesinger N, Van der Heijde D, Landewe RB. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014;9:CD010120.
  115. Punzi L, Scanu A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev 2012;12:66-71.
  116. Van Echteld I, Wechalekar MD, Schlesinger N, Buchbinder R, Aletaha D. Colchicine for acute gout. Cochrane Database Syst Rev 2014;8:CD006190.
  117. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z.J Med 1987;17:301-4.
  118. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 2010;62:1060-8.
  119. Anonymus. Colchicine onofficieel geregistreerd. Gebu 1999;33:36.
  120. KNMP. Informatorium medicamentorum (2017). Den Haag: KNMP, 2017.
  121. Gast LF, Cats A. Geneesmiddelen tegen jicht. Ned Tijdschr Geneeskd 1988;132:1827-31.
  122. Wallace SL. Colchicine. Semin Arthritis Rheum 1974;3:369-81.
  123. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988;14:441-57.
  124. Conaghan PG, Day RO. Risks and benefits of drugs used in the management and prevention of gout. Drug Saf 1994;11:252-8.
  125. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
  126. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1981;10:231-54.
  127. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med 1996;100:46S-52S.
  128. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 2013;4:CD009920.
  129. Wechalekar MD, Vinik O, Moi JH, Sivera F, Van Echteld IA, Van Durme C, et al. The efficacy and safety of treatments for acute gout: Results from a series of systematic literature reviews including cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors. J Rheumatol Suppl 2014;92:15-25.
  130. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. Eular evidence based recommendations for gout. Part ii: management. Report of a task force of the eular standing committee for international clinical studies including therapeutics (escisit). Ann Rheum Dis 2006;65:1312-24.
  131. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
  132. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. Jama 2008;300:924-32.
  133. Kanbay M, Ozkara A, Selcoki Y, Isik B, Turgut F, Bavbek N, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-33.
  134. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet 2010;375:2161-7.
  135. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
  136. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006;114:2508-16.
  137. Reinders MK, Haagsma C, Jansen TL, Van Roon EN, Delsing J, Van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann Rheum Dis 2009;68:892-7.
  138. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 american college of rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
  139. NVR. Richtlijn jicht (2013). Ga naar bron
  140. Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002;47:356-60.
  141. Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ. Allopurinol for chronic gout. Cochrane Database Syst Rev 2014;10:CD006077.
  142. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004;51:321-5.
  143. Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O’Hanlon CE, Tariq A, et al. Management of gout: a systematic review in support of an american college of physicians clinical practice guideline. Ann Intern Med 2017;166:37-51.
  144. Hill EM, Sky K, Sit M, Collamer A, Higgs J. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. J Clin Rheumatol 2015;21:120-5.
  145. Taylor TH, Mecchella JN, Larson RJ, Kerin KD, Mackenzie TA. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. Am J Med 2012;125:1126-34.e7.
  146. Kydd AS, Seth R, Buchbinder R, Edwards CJ, Bombardier C. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014;11:CD010457.
  147. Faruque LI, Ehteshami-Afshar A, Wiebe N, Tjosvold L, Homik J, Tonelli M. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 2013;43:367-75.
  148. De Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH, et al. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum 2003;48:2415-24.
  149. Hurkmans E, Van der Giesen F, Bloo H. Kngf-richtlijn reumatoide artritis. Nederlands Tijdschrift voor Fysiotherapie 2008;118:1-36.
  150. Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Alvaro-Gracia JM, et al. 2016 update of the eular recommendations for the management of early arthritis. Ann Rheum Dis 2017;76:948-59.
NHG-werkgroep:
Janssens HJEM, Lopuhaä DE, Schaafstra A, Shackleton DP, Van der Helm-Van Mil AHM, Van der Spruit R, Van Peet PG, Wiersma, Tj, Woutersen-Koch H
7 gerelateerde lacunesGerelateerd onderzoek
E-mail